Dialysis independence following combination daratumumab, thalidomide, bortezomib, cyclophosphamide, and dexamethasone in multiple myeloma with severe renal failure
Clinical Lymphoma Myeloma and Leukemia(2020)
摘要
There is limited data to support the use of daratumumab-containing regimens for patients with multiple myeloma presenting with severe renal failure requiring hemodialysis. We describe a case of successfully achieving dialysis independence with the use of combination daratumumab, bortezomib, thalidomide, cyclophosphamide, and dexamethasone in a patient who had become dialysis-dependent secondary to severe myeloma-induced renal failure. (C) 2020 Elsevier Inc. All rights reserved.
更多查看译文
关键词
Daratumumab,Hemodialysis,Monoclonal antibody,Multiple myeloma,Renal impairment
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要